Hunting for a new gold standard in longevity
Lifespan.io (LEAF) - 01-Nov-2024Ora biomedical’s high-tech screening could uncover life-extending compounds beyond rapamycin’s reach
Join the club for FREE to access the whole archive and other member benefits.
Chief Executive Officer and co-founder of Ora Biomedical
Dr. Mitchell Lee is the CEO of Ora Biomedical, with research interests focused on identifying therapeutics for healthy aging, understanding the links between aging and age-related diseases, and exploring how natural genetic variation influences disease outcomes and therapeutic effectiveness. He has received multiple NIH training grants and was awarded the prestigious Howard Hughes Medical Institute (HHMI) Gilliam Fellowship for Advanced Study in 2015, as well as awards for his science communication efforts.
Throughout his career, Dr. Lee has mentored over 45 researchers and was awarded the UW Undergraduate Research Mentor Award in 2018. He also founded the American Aging Association (AGE) Trainee Chapter, serving on its Executive Committee and Board of Directors.
Dr. Lee holds a B.S. in Biology and a B.A. in Philosophy, an M.S. in Biology from Western Washington University, a PhD in Experimental Pathology from the University of Washington, and a Biotechnology Project Management certificate from UW/UCSD.
Visit website: https://orabiomedical.com/team/
See also: Ora Biomedical - A Seattle-based pharmaceutical startup in the longevity biotechnology industry
Details last updated 14-Sep-2024
Matt and Mitchell Lee discuss the current state of drug discovery in the longevity field
Ora biomedical’s high-tech screening could uncover life-extending compounds beyond rapamycin’s reach